Drug
SAM-531 clinical trials
Also written SAM-531.
- studies test it
- 11
- open now
- 0
- in phase 3
- 0
- first study started
- 2006
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
11 studies that test it; most in 2006 (3)
| Year | Studies |
|---|---|
| 2006 | 3 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 0
Wyeth is now a wholly owned subsidiary of Pfizer (9) · Pfizer (2)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses SAM-531 is read from its arms, and is right about nine times in ten.
Testing it · 11
- Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer DiseaseTerminatedPhase 2PfizerNCT00895895Written as SAM-531 1.5 mg
- To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy VolunteersCompletedPhase 1PfizerNCT01253655Written as PF-05212365
- Study Evaluating Potential Interaction Between SAM-531 And Gemfibrozil When Co-AdministeredCompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00966966Written as SAM-531 and gemfibrozil
- Study Evaluating The Potential Interaction Between Verapamil Immediate Release And SAM-531 When Co-AdministeredCompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00745576Written as SAM-531
- Study Evaluating the Safety,Tolerability, PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimer's DiseaseCompletedPhase 2Wyeth is now a wholly owned subsidiary of PfizerNCT00481520Written as SAM-531
- Study Evaluating How Quickly And To What Extent The 14-Carbon-SAM-531 Is Absorbed/Converted/Eliminated In Male SubjectsCompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00906191Written as SAM-531
- Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Japanese MalesCompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00479297Written as SAM-531
- Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531CompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00479349Written as SAM-531
- Study Evaluating Effects of SAM-531 on Sleep Electroencephalogram (EEG) and Quantitative Wake EEG in Healthy SubjectsCompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00519298Written as SAM-531
- Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Young and Elderly SubjectsCompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00480818Written as SAM-531
- Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy SubjectsCompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00479700Written as SAM-531